Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2576-2582

  Chue, Colin D ^a   Edwards, Nicola C ^a   Davis, Laura J ^a   Steeds, Richard P ^a   Townend, Jonathan N ^a   Ferro, Charles J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

arterial stiffness; phosphate; progression of chronic kidney disease; pulse wave velocity

Indexed keywords

PHOSPHATE;

ADULT; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

BLOOD FLOW VELOCITY; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PHOSPHATES; PROGNOSIS; PROSPECTIVE STUDIES; PULSATILE FLOW;

EID: 79960724020     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq787     Document Type: Article

References (44)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305
2. Chue CD, Townend JN, Steeds RP et al. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010;96:817-823
3. Matsushita K, Selvin E, Bash LD et al. Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol 2009;20:2617-2624
4. Shlipak MG, Katz R, Kestenbaum B et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009;20:2625-30
5. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617
6. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-885 (Pubitemid 46762749)
7. Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-2633 (Pubitemid 41532599)
8. Levin A, Djurdjev O, Beaulieu M et al. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008;52:661-671
9. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in predialysis patients. Nephrol Dial Transplant 2007;22:2909-2916 (Pubitemid 350093423)
10. Norris KC, Greene T, Kopple J, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006;17:2928-2936 (Pubitemid 44484684)
11. Connolly GM, Cunningham R, McNamee PT et al. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 2009;87:1040-1044
12. Moore J, Tomson C R V, Tessa Savage M et al. Serum phosphate and calcium concentrations are associated with patient survival following kidney transplantation. Clin Transplant 2010; DOI: 10.1111/j.1399-0012.2010.01292.x
13. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-2605 (Pubitemid 44627304)
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-S266
15. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470 (Pubitemid 29135798)
16. O'Brien E, Mee F, Atkins N et al. Evaluation of three devices for selfmeasurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit 1996;1:55-61 (Pubitemid 126441351)
17. Reinders A, Reggiori F, Shennan AH. Validation of the DINAMAP ProCare blood pressure device according to the international protocol in an adult population. Blood Press Monit 2006;11:293-296 (Pubitemid 44319048)
18. Williams B, Poulter NR, Brown MJ et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-185 (Pubitemid 38425770)
19. Wilkinson IB, Fuchs SA, Jansen IM et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens 1998;16:2079-2084 (Pubitemid 29002391)
20. Savage MT, Ferro CJ, Pinder SJ et al. Reproducibility of derived central arterial waveforms in patients with chronic renal failure. Clin Sci (Lond) 2002;103:59-65 (Pubitemid 34729125)
21. Ferro CJ, Savage T, Pinder SJ et al. Central aortic pressure augmentation in stable renal transplant recipients. Kidney Int 2002;62:166-171 (Pubitemid 34754059)
22. Wilkinson IB, MacCallum H, Flint L et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;525 Pt 1:263-270 (Pubitemid 30311951)
23. Wimmer NJ, Townsend RR, Joffe MM et al. Correlation between pulse wave velocity and other measures of arterial stiffness in chronic kidney disease. Clin Nephrol 2007;68:133-143 (Pubitemid 47377336)
24. Ford ML, Tomlinson LA, Chapman TP et al. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010;55:1110-1115
25. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997;51:1908-1919 (Pubitemid 27252762)
26. Jungers P, Hannedouche T, Itakura Y et al. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant 1995;10:1353-1360
27. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;76:S1-S130
28. Schwarz S, Trivedi BK, Kalantar-Zadeh K et al. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006;1:825-831
29. Ferro CJ, Chue CD, Steeds RP et al. Is lowering phosphate exposure the key to preventing arterial stiffening with age? Heart 2009;95:1770-1772
30. Haut LL, Alfrey AC, Guggenheim S et al. Renal toxicity of phosphate in rats. Kidney Int 1980;17:722-731 (Pubitemid 10040360)
31. Loghman-Adham M. Role of phosphate retention in the progression of renal failure. J Lab Clin Med 1993;122:16-26 (Pubitemid 23206870)
32. Ibels LS, Alfrey AC, Haut L et al. Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 1978;298:122-126
33. Nagano N, Miyata S, Obana S et al. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2003;18:2014-2023 (Pubitemid 37220306)
34. Cozzolino M, Staniforth ME, Liapis H et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003;64:1653-1661 (Pubitemid 37323693)
35. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218 (Pubitemid 39031360)
36. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528 (Pubitemid 41725150)
37. Upadhyay A, Hwang SJ, Mitchell GF et al. Arterial stiffness in mild-to-moderate CKD. J Am Soc Nephrol 2009;20:2044-2053
38. Taal MW, Sigrist MK, Fakis A et al. Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5. Nephron Clin Pract 2007;107:c177-c181
39. Takenaka T, Mimura T, Kanno Y, et al. Qualification of arterial stiffness as a risk factor to the progression of chronic kidney diseases. Am J Nephrol 2005;25:417-424 (Pubitemid 41433884)
40. Takenaka T, Mimura T, Kikuta T et al. Time for reflection predicts the progression of renal dysfunction in patients with nondiabetic chronic kidney disease. Clin Exp Hypertens 2009;31:220-230
41. Rajzer MW, Wojciechowska W, Klocek M et al. Comparison of aortic pulse wave velocity measured by three techniques: Complior, SphygmoCor and Arteriograph. J Hypertens 2008;26:2001-2007
42. McEniery CM, Yasmin Hall IR et al. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005;46:1753-1760 (Pubitemid 41531635)
43. Covic A, Fliser D, Goldsmith D et al. Promoting scientific collaboration and education in cardiovascular-renal medicine. EURECAM: An ERA-EDTA-based working group. Nephrol Dial Transplant Plus 2009;2:522-525
44. Tomlinson L, Ben-Shlomo Y, Caplin B et al. Renal disease is associated with accelerated vascular ageing: initial results of the UK research alliance into kidney disease and arterial stiffness (UREKA) collaboration. Abstract presentation at the British Renal Society/Renal Association Joint Conference, Manchester, UK, 2010